Methylglyoxal Evaluation in Humans
MEH
A Cross-Sectional Trial of Methylglyoxylated-Protein Levels in Adults With Chronic Pain
MEH
A Cross-Sectional Trial of Methylglyoxylated-Protein Levels in Adults With Chronic Pain
Sponsor study identifier
observational
39
1 country
1
Study Start
May 2, 2022
Actual (reported)Primary Completion
April 1, 2025
Actual (reported)Study Completion
April 1, 2025
Actual (reported)The investigators will test the hypothesis that patients with low back pain associated with lumbar disc aberrancy will have elevated MGO-protein levels circulating in the blood that are comparable to patients with painful diabetic neuropathy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 1, 2025
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 6, 2022
Actual (reported)April 28, 2022
Actual (reported)May 2, 2022
Actual (reported)April 1, 2025
Actual (reported)April 1, 2025
Actual (reported)Methylglyoxal Evaluation
Number of participants with elevated blood methylglyoxal-derived hydroimidazolone (MG-H1, nM) with chronic pain.
12 months
HbA1c
12 months
Blood Glucose
12 months
Neurofilament Light
12 months
Glyoxylase 1 Activity
12 months
Body Mass Index
12 months
Patients 45-75 years of age without Type 2 Diabetes and without chronic low back pain.
Patients 45-75 years of age with Type 2 Diabetes and experiencing painful neuropathy (painful numbness or tingling in hands and/or feet)
Patients 45-75 years of age with chronic low back pain as a direct result of non-operative lumber disc aberrancy (lumbar disc herniation, protrusion, or extrusion).
Based on their pain status, subjects will be distributed into three groups: healthy, type 2 diabetes with painful neuropathy, and chronic low back pain. Subjects will not be randomized as our studies are based on comparisons of subjects within the 3 groups. The study team will assess for the presence of neuropathy by verbal confirmation of the subject. Subjects placed within the chronic low back pain group must have a diagnosis of chronic pain symptoms (persistent pain lasting longer than 3 months), as a direct result of lumbar disc aberrancy in the last 12 months. The study team will require diagnostic imaging to confirm aberrancy status for enrollment in this group.
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Doug Wright, PhD
University of Kansas Medical Center
39 participants (actual enrollment reported by the registry).
First Submitted
April 6, 2022
First Posted
April 28, 2022
Study Start
May 2, 2022
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
April 1, 2025
Actual (reported)Study Completion
April 1, 2025
Actual (reported)Last Updated
April 4, 2025
Record last verified: 2025-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: